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Background and purpose: Gram-negative bacteria contain ligands for Toll-like receptor (TLR) 4 and nucleotide oligomeriza-
tion domain (NOD) 1 receptors. Lipopolysaccharide (LPS) activates TLR4, while peptidoglycan products activate NOD1.
Activation of NOD1 by the speciﬁc agonist FK565 results in a profound vascular dysfunction and experimental shock in vivo.
Experimental approach: Here, we have analysed a number of pharmacological inhibitors to characterize the role of key
signalling pathways in the induction of NOS2 following TLR4 or NOD1 activation.
Key results: Vascular smooth muscle (VSM) cells expressed NOD1 mRNA and protein, and, after challenge with Escherichia coli
or FK565, NOS2 protein and activity were induced. Macrophages had negligible levels of NOD1 and were unaffected by
FK565, but responded to E. coli and LPS by releasing increased NO and expression of NOS2 protein. Classic pharmacological
inhibitors for NF-kB (SC-514) and mitogen-activated protein kinase (SB203580, PD98059) signalling pathways inhibited
responses in both cell types regardless of agonist. While TLR4-mediated responses in macrophages were speciﬁcally inhibited
by the pan-caspase inhibitor z-VAD-fmk and the PKC inhibitor Gö6976, NOD1-mediated responses in VSM cells were inhibited
by the Rip2 inhibitor PP2.
Conclusions and implications: Our ﬁndings suggest a selective role for NOD1 in VSM cells, and highlight NOD1 as a potential
novel therapeutic target for the treatment of vascular inﬂammation.
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Introduction
It is now clear that pattern recognition receptors (PRRs) are
intrinsically involved in cardiovascular diseases including
atherosclerosis (Michelsen et al., 2004). Moreover, Toll-like
receptor (TLR) 4, the receptor for Gram-negative lipopolysac-
charide (LPS), or TLR2, the receptor for Gram-positive
lipoteichoic acid, is expressed on vascular cells and in vessels
where they sense pathogens directly (without the require-
ment of macrophages), leading to induction of inﬂammatory
genes including NOS 2 (Cartwright et al., 2007a,b) and COX-2
(Jimenez et al., 2005). Our recent work has shown that acti-
vation of the PRR nucleotide oligomerization domain (NOD)
1 on vascular smooth muscle (VSM) cells leads to profound
induction of NOS2 in vitro and vascular collapse in vivo (Cart-
wright et al., 2007a). NOD1 and NOD2 are receptors for prod-
ucts of the synthesis and degradation of peptidoglycan (PGN)
from Gram-negative bacteria (Chamaillard et al., 2003; Masu-
moto et al., 2006; Park et al., 2007). Thus, TLR4 and NOD1 are
both receptors for different pathogen-associated molecular
patterns (PAMPs) from Gram-negative bacteria. Importantly,
others have shown that, in leucocyte populations, activation
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that co-stimulation with TLR agonists can result in
increased responses (Chamaillard et al., 2003; Fritz et al.,
2005; van Heel et al., 2005; Tada et al., 2005; Masumoto
et al., 2006). However, work from our group and others have
shown that activation of NOD receptors alone results in
induction of inﬂammatory genes in some types of cell,
including VSM cells (Cartwright et al., 2007b; Park et al.,
2007). However, the mechanism by which activation of
NOD1 in VSM cells results in inﬂammation was not previ-
ously studied. Thus, in the current study, we have compared
responses in VSM and macrophages to speciﬁc ligands for
TLR4 and NOD1, and measured NOS2 activity as a relevant
readout of cell activation. Our ﬁndings show, for the ﬁrst
time, that NOD1 receptors are selectively expressed in VSM
cells. We also go on to establish similarities and differences
in how NOD1 versus TLR4 activation (in VSM cells vs. mac-
rophages, respectively) signal resulting in the induction of
NOS2. These observations provide important new informa-
tion about how vascular cells sense pathogens and danger
signals, which may well have direct relevance to our




Clonal populations of VSM cells with a contractile (‘spindle’)
phenotype derived from the mixed polyclonal rat aortic VSM
cell line WKY12-22 were kindly provided by Professor
Timothy Warner (William Harvey Research Institute, London,
UK). J774.2, a murine macrophage cell line, was obtained
from the European collection of cell cultures. Murine perito-
neal macrophages were collected from C57BL/6 mice or
Wistar–Kyoto rats by peritoneal lavage (Terenzi et al., 1995).
Cells were cultured as described previously (Jimenez et al.,
2005) using Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% FBS and antibiotic/mycotic mix. Cells were
treated for 24 (VSM and J774.2 cells) or 48 (rat peritoneal
macrophages) hours with either FK565 (10 nM, NOD1
agonist), LPS (1 mg·mL
-1, TLR4 agonist) or whole heat-killed
Escherichia coli (3 ¥ 10
7 CFU·mL
-1). In some experiments, cells
were pretreated for 60–90 min with pharmacological inhibi-
tors of different signalling cascades before the addition of
bacterial ligands.
Measurement of NO production
NO production by cells was measured by the accumulation of
its oxidation product, nitrite, using the Griess reaction, as we
have described previously (Jimenez et al., 2005; Paul-Clark
et al., 2006). Nitrite levels obtained in the presence of differ-
ent inhibitors are expressed as a percentage of the response to
the agonist alone.
Measurement of 6-keto prostaglandin (PG) F1a
COX activity was measured by the accumulation of 6-keto
PGF1a, the stable hydrolysis product of prostacyclin (PGI2),
by speciﬁc radioimmunoassay (Bishop-Bailey et al., 1997;
Jimenez et al., 2005).
Assessment of cell respiration by
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT)
Cell respiration, a marker of viability, was assessed after all
treatments by measuring the reduction of MTT (Sigma
Chemical Company, Poole, Dorset, UK) to formazan. Unless
shown in Supporting Information Tables S1 and S2, none of
treatments affected cell viability.
Measurement of NOS2, COX-2 and NOD1 protein expression
Western blot analysis using speciﬁc NOS2 (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), NOD1 (1:1000, Cell
Signaling Technology, New England Biolabs Ltd., Hitchin,
Hertfordshire, UK) and COX-2 (1:1000; Cayman Chemical,
Ann Arbor, MI, USA) antibodies was performed as previously
described (Jimenez et al., 2005; Paul-Clark et al., 2006; Cart-
wright et al., 2007a). The expression of NOD1 was also analy-
sed on murine macrophages collected from C57BL/6 mice by
peritoneal lavage (Bosca et al., 2005).
Measurement of NOD1 mRNA expression
Reverse transcription–PCR (RT–PCR) analysis was performed
as previously described (Cartwright et al., 2007a). Total RNA
was extracted using RNeasy Minikit (Qiagen, Crawley, UK),
and converted into complementary DNA by RT following the
protocol of the manufacturer (Omniscript Reverse Transcrip-
tion kit, Qiagen). Primers for the PCR were selected from the
regions of the NOD1 mRNA sequence with the highest degree
of homology in rat (NM_001109236.1, GenBank) and mouse
(NM_172729.2, GenBank). Both sequences were compared
with GenBank using the Blast software (National Center for
Biotechnology Information website). The following primers,
synthesized on request by Invitrogen (Paisley, UK), were used
for the ampliﬁcation of NOD1; sense: 5′- GTC CTC AAC GAG
CAT GGC GAG ACT -3′ and antisense: 5′-TGC AGC TCA TCC
AGG CCG TCA A-3′ resulting in a product of 302 bp; and for
b-actin, sense: 5′-GAT CAT GTT TGA GAC CTT CAA CAC C-3′
and antisense: 5′-GTT TCA TGG ATG CC ACA GGA TTC-3′,
which yielded a product of 467 bp. In preliminary experi-
ments, we tested a number of cycles ranging from 24 to 35,
with cDNA diluted over a range of three magnitudes, to estab-
lish the linearity of the reaction. PCR of NOD1 was performed
using a MyCycler Thermal cycler (Bio-Rad, Hercules, CA, USA)
by using Taq PCR Master Mix Kit (Qiagen) for 30 cycles (94°C
for 45 s, 64.7°C for 45 s and 72°C for 45 s) followed by a ﬁnal
extension step at 72°C for 10 min. The same protocol was
used for b-actin except for the annealing temperature, which
was 60.4°C. The products of the PCR were separated in 2%
agarose gels stained with ethidium bromide, and bands were
quantiﬁed using image analysis software (Quantity One, Bio-
Rad). Results were normalized to the bands of b-actin from the
same samples.
Drugs and bacterial ligands
Heat-killed E. coli suspensions were prepared as previously
described (Cartwright et al., 2007a) from a clinical blood
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(heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-
alanine), a generous gift from Professor David Van Heel
(QMUL, London, UK), was obtained from Fujisawa Pharma-
ceutical (Osaka, Japan), the NOD2 agonist MDP (muramyl
N-acetylmuramyl-L-alanyl-D-isoglutamine, also known as
muramyl dipeptide) was purchased from Invivogen (San
Diego, CA, USA), the cell-permeable JNK peptide inhibitor
D-JNKi ((D)-hJIP[175-157]-DPro-DPro-(D)-HIV-TAT[57-48]) was
purchased from Enzo Life Sciences (Exeter, UK) and the TLR4
agonist LPS (from E. coli 055:B5) was purchased from Sigma.
All other drugs were obtained from Calbiochem (San Diego,
CA, USA). Drugs were dissolved initially in dimethyl sulphox-
ide (DMSO) (except for LPS and FK565, which were dissolved
in PBS) to prepare a 0.1 or 0.01 mol·L
-1 stock solution; further
dilutions were made in DMEM. The maximum concentration
of DMSO achieved in any experiment, 0.3%, did not show
signiﬁcant effects on cell viability.
Statistical analysis
Results were normalized to ‘control’ in most ﬁgures, expressed
as mean  SEM, and were analysed by Student’s one sample
t-test. Values of P < 0.05 were considered to be signiﬁcant.
Results
Effect of NOD1 or TLR4 activation on NOS2 activity in VSM
cells and macrophages
We have recently shown that FK565 activates the VSM com-
ponent of intact blood vessels via a NOD1-speciﬁc pathway
resulting in NOS2 induction and vascular dysfunction (Cart-
wright et al., 2007b). The effect of FK565 was found to be
independent of TLR4 or TLR adapter proteins (Cartwright
et al., 2007b). Here, we have conﬁrmed that FK565 induces
NOS2 activity (Figure 1A and Supporting Information Fig-
ure S1) and protein expression (Figure 1C) in cultured VSM
cells. Furthermore, NOS2 induction was accompanied by an
increase in the activity and protein expression of COX2
(Supporting Information Figure S1), another enzyme
involved in the production of key vasoactive inﬂammatory
mediators (such as prostacyclin). NOS2 activity and
protein were also induced in VSM cells stimulated with
whole Gram-negative E. coli and, to a lesser extent, LPS
(Figure 1A,C). Similarly, J774.2 murine macrophages showed
increased levels of NOS2 activity (Figure 1B) and protein
(Figure 1D) when stimulated with E. coli or LPS. However, in
direct contrast to results seen in VSM cells, FK565 had no
effect on NOS2 activity in macrophages (Figure 1B,D). VSM
cells and J774.2 macrophages were unaffected by the NOD2
agonist MDP (nitrite mM; VSM cells: basal, 0.0  0.0; plus
10 mM MDP, 0.8  0.4; macrophages: basal, 1.0  0.9, plus
10 mM MDP, 0.0  0.0; n = 9; 24 h). In order to ensure these
observations were not due to any species differences, we per-
formed separate studies using primary cultures of rat mac-
rophages. Similar to experiments using murine J774
macrophages, rat macrophages released increased levels of
NO when stimulated with LPS, but not FK565 (nitrite mM;
basal, 0  0; plus 1 mg·mL
-1 LPS, 28  10; plus 10 nM FK565,
0  0; n = 6; 48 h). In line with these observations, VSM
cells expressed clear detectable levels of NOD1 protein,
while both J774.2 and freshly elicited mouse macrophages
expressed low or undetectable levels of NOD1 protein
(Figure 1E,F). These ﬁndings were conﬁrmed by RT–PCR
(Figure 1G,H). Levels of NOD1 gene expression (NOD1/b-
actin) were not altered by stimulation of cells with FK565
for 24 h (VSM cells: control 0.100  0.030, plus FK565 0.147
 0.033; J774.2 macrophages: 0.006  0.002, plus FK565
0.003  0.006). In previous studies, enhancement of TLR4-
induced secretion of pro-inﬂammatory cytokines (including
IL-1b, IL-6 or IL-8) by NOD1 stimulation has been shown in
macrophages and dendritic cells (Chamaillard et al., 2003;
Fritz et al., 2005; Masumoto et al., 2006). In our study, we
found no interaction between FK565 and LPS for the induc-
tion of NOS2 in macrophages (co-stimulation with 10 nM
FK565 plus 1 mg·mL
-1 LPS induced 105  5.2% of nitrite
produced by 1 mg·mL
-1 LPS alone). In VSM cells, there was a
small, but statistically signiﬁcant, increase in the ability of
FK565 to induce NOS2 activity when cells were co-treated
with threshold concentrations of LPS (co-stimulation with
0.1 mg·mL
-1 LPS plus 10 nM FK565 induced 132  5.6% of
nitrite produced by FK565 alone, P < 0.05).
Role of NF-kB, MAP kinases, PKC and RIP2 in responses
induced by NOD1 compared to those induced by TLR4 in VSM
cells and macrophages
In different cell types, induction of NOS2 by a variety of
agents is sensitive to inhibition by corticosteroids. In this
study, we found that NOS2 activity and protein expression
induced by either FK565 in VSM cells or by LPS in macroph-
ages were inhibited by dexamethasone (Figure 2A–D;
Supporting Information Table S3). The I-kB kinase (IKK)-2-
inhibitor SC-514 (4-amino-[2′,3′-bithiophene]-5-carbox
amide) (Kishore et al., 2003) inhibited NOS2 activity and
protein expression in VSM cells stimulated with FK565
(Figure 2E,G; Supporting Information Table S3) or macroph-
ages (Figure 2F,H; Supporting Information Table S3). Simi-
larly, SC-514 inhibited NOS2 activity induced by whole E. coli
in VSM cells and macrophages (Supporting Information
Table S4). The p38 and extracellular signal-regulated (ERK)
mitogen-activated protein kinase (MAPK) inhibitors
SB 203580 (4-[5-(4-ﬂuorophenyl)-2-[4-(methylsulphonyl)
phenyl]-1H-imidazol-4-yl]pyridine) and PD 98059 (2-(2-
amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) (Davies
et al., 2000), respectively, inhibited NOS2 activity and protein
expression in VSM cells stimulated with FK565 or macroph-
ages stimulated with LPS (Figure 3; Supporting Information
Table S3). NOS2 activity induced in macrophages by LPS was
inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP
600125 (anthra[1-9-cd]pyrazol-6(2H)-one) (Bennett et al.,
2001) (Figure 3; Supporting Information Table S4), but not by
the cell-permeable JNK peptide inhibitor D-JNKi ((D)-hJIP[175-
157]-DPro-DPro-(D)-HIV-TAT[57-48]) (Borsello and Bonny,
2004). By contrast, SP 600125 showed a weak trend to inhibit
NOS2 activity induced by FK565 in VSM cells, while D-JNKi
induced a statistically signiﬁcant inhibition of activity in
these cells (Figure 3; Supporting Information Tables S3 and
S4). These results are in contrast to those found in cells stimu-
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where SP 600125 inhibited NOS2 activity in both VSM cells
and macrophages. Gö6983 (3-[1-[3-(dimethylamino) propyl]-
5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-
dione), which at the concentration tested is a selective
inhibitor of conventional (a, bI, bII, g), some novel (d) and
atypical (i/l, z) isoforms of PKC (Way et al., 2000), had no
effect on NOS2 activity induced in VSM cells by FK565 or
macrophages induced by LPS (Figure 4). Gö6976 (5,6,7,13-
tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-12-propanenitrile), which, in addition to
conventional isoforms, inhibits PKCm (Way et al., 2000), also
had no effect on NOS2 activity induced by FK565 in VSM
cells. By contrast, Gö6976 inhibited NOS2 activity induced by
LPS in macrophages (Figure 4). Similar results were found
when cells were stimulated with whole E. coli. The Src
family kinase inhibitor PP2 (3-(4-chlorophenyl) 1-(1,1-
dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine), at
concentrations reported to inhibit RIP2 [EC50 = 100 nM for Src
and EC50 = 10 nM for RIP2 (Windheim et al., 2007)] inhibited
NOS2 activity induced in VSM cells stimulated with either
FK565 or whole E. coli, but had little or no effect on activity
induced in macrophages stimulated with LPS or whole E. coli
(Figure 5, Supporting Information Table S4).
Figure 1 Effects of Gram-negative PAMPs on NO release by cultured VSM cells and macrophages, and expression of NOD1 in VSM cells and
macrophages. (A) At 24 h, Escherichia coli (EC; 3 ¥ 10
7 CFU·mL-1), LPS (1 mg·mL-1) or FK565 (10 nM) induced signiﬁcant increases in release
of NO from VSM cells. NO was measured by the oxidation product nitrite by Griess assay, and compared to cells incubated in media alone
(CTRL). (B) Escherichia coli and LPS induced signiﬁcant release of NO in J774.2 macrophages. In contrast, FK565 did not signiﬁcantly increase
the release of NO. Data are presented as the mean  SEM from n = 6 determinations for J774.2 cells and n = 18 for VSM cells. (C,D)
Representative Western blots of NOS2 (ª130 kDa) and b-actin (ª47 kDa) from VSM cells (C) and macrophages (D) treated with E. coli, LPS or
FK565 for 24 h. (E) Representative Western blot of NOD1 protein (ª95 kDa) in VSM, J774.2 or freshly isolated peritoneal macrophages from
C57 BL/6 mice. Detectable NOD1 expression was only seen in VSM cells. (F) Densitometric data analysis of NOD1 protein normalized to b-actin
levels and expressed as arbitrary units (AU). Data are presented as the mean  SEM from n = 3. (G) Ethidium bromide-stained agarose gels
containing RT–PCR products of NOD1 (302 bp) and b-actin (467 bp) in VSM cells and J774.2 macrophages. Detectable NOD1 expression was
only seen in VSM cells. (H) Densitometric data analysis of NOD1 mRNA normalized to b-actin levels and expressed as AU. Data are presented
as the mean  SEM from n = 3.
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responses in VSM cells and macrophages
Activation of several NOD-like receptors (NLRs) from the
NALP subfamily has also been linked to the formation of an
inﬂammasome, leading to the activation of caspase, which
processes pro-IL-1b into mature IL-1b to initiate an
inﬂammatory response. Neither the pan-caspase inhibitor
(Garcia-Calvo et al., 1998) Z-VAD-fmk (benzyloxycarbonyl-
Val-Ala-Asp(OMe)-ﬂuoromethylketone; Figure 6A) nor
binding antibodies for IL-1b or IL-18 (Figure 6C) affected
NOS2 activity induced in VSM cells stimulated with FK565. By
contrast, Z-VAD-fmk inhibited NOS2 activity and protein
expression in J774.2 macrophages stimulated with whole E.
coli or LPS (Figure 6B,D; Supporting Information Tables S3
and S4). However, this was associated with a direct effect of
the drug on cell viability (Supporting Information Tables S1
and S2). The selective inhibition of caspase 1 and caspase
8 isoforms by Z-WEHD-fmk (benzyloxycarbonyl-Trp-
Glu(OMe)-His-Asp(OMe)-ﬂuoromethylketone) and Z-IETD-
fmk (benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-ﬂuo
romethylketone) (Maelfait et al., 2008), respectively, mim-
icked the effects of Z-VAD-fmk on NOS2 induction while
preserving cell viability (Figure 6F).
Discussion
It is now well accepted that stromal cells of the vasculature,
including VSM cells, sense pathogens and danger signals
directly, and that this is important for the development of
Figure 2 Role of corticosteroids and NF-kB on TLR4 and NOD1-induced NO production and NOS2 expression in VSM and J774 cells. VSM
cells (A,E) and J774.2 macrophages (B,F) were treated with increasing concentrations of dexamethasone (0.01–10 mM; A,B) or the IKK 2
inhibitor SC-514 (0.1–30 mM; E,F). NOS2 was induced in VSM cells with FK565 (10 nM) and in macrophages with LPS (1 mg·mL
-1). Data were
collected from n = 9–12 for J774.2 cells and n = 6 for VSM cells and expressed as a percentage of the response induced by FK565 or LPS,
respectively (CTRL). Western blotting (C,D,G,H) for NOS2 protein showed that dexamethasone (1 mM; C,D) and SC-514 (10 mM; G,H)
inhibited protein expression in both VSM cells (C,E) and macrophages (D,H) at 24 h (n = 3–4). Data were analysed using one-sample t-test for
normalized data, *P < 0.05, **P < 0.01 and ***P < 0.001.
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identiﬁed a clear difference in how VSM and macrophages
sense NOD1 agonists. NOD1 receptors are PRR for PAMPs of
Gram-negative bacteria. VSM cells express NOD1 receptors
and respond to agonists by expressing increased NOS2. By
contrast, macrophages do not express NOD1 receptors and are
unresponsive to the selective agonist FK565. Our ﬁndings also
suggest that the signalling pathways for NOD1 and TLR4 are
separate, but converge at the level of NF-kB and MAPK acti-
vation for NOS2 induction.
In the current study, we found that the synthetic NOD1
agonist FK565 induced profound increases in NO release and
increased expression of NOS2 protein in VSM cells. Similarly
VSM cells showed increased levels of COX-2 activity and
expression when stimulated with FK565. These observations
conﬁrm our previous results showing that activation of NOD1
in murine blood vessels induces NOS2 activity and vascular
dysfunction (Cartwright et al., 2007a). Our previous studies
conﬁrmed that these actions of FK565 are totally speciﬁc to
NOD1 receptors in vitro and are accompanied by extensive
vascular collapse and shock in vivo (Cartwright et al., 2007a).
In that model of shock, the decline in blood pressure is
directly associated with the induction of NOS2 in blood
vessels (Szabo et al., 1993). We also found that the PAMP for
TLR4, LPS induced NOS2 activity in our cultures of VSM cells,
although the magnitude of response was reduced compared
to the response we obtained when cells were stimulated with
FK565. This observation is also in line with, and explains, our
previous study where the ‘shock’ induced by FK565 in vivo was
far greater than that induced by LPS (Cartwright et al., 2007a).
It is therefore signiﬁcant to note that in VSM, NOD1 appears
to dominate TLR4 responses when it comes to induction of
NOS2. Importantly, the reverse seems to be true for macroph-
ages. As expected, we found that LPS induced a robust induc-
Figure 3 Role of MAPKs in TLR4 and NOD1 signalling pathways. Regulation of nitrite production in VSM cells (A, C, E, G) and macrophages
(B, D, F, H) by the p38 MAPK inhibitor SB 203580 (0.01–10 mM), the ERK 1/2 inhibitor PD 98059 (0.01–100 mM) and the JNK inhibitors SP
600125 (0.1–30 mM) and D-JNKi (0.1–30 mM). Data are presented as the mean  SEM of n = 6–9 for J774.2 cells, and n = 9–15 for VSM cells,
and are expressed as a percentage of the response to the FK565 or LPS alone (CTRL). Representative Western blotting images for NOS2 protein
(G,H) showing the effects of SB 203580 (1 mM), PD 98059 (10 mM) and SP 600125 (30 mM) on NOS2 expression in VSM cells (G) and
macrophages (H). Data were analysed using one-sample t-test for normalized data, *P < 0.05 and ***P < 0.001, n = 3–4.
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J774, and in primary cultures of rat macrophages. By contrast,
we found that the NOD1 agonist FK565 was completely inac-
tive as an inducer of NOS2 activity or protein. In line with
these observations, we found that VSM cells expressed detect-
able levels of NOD1 mRNA and protein, while macrophages
did not. NOD2 signalling is often studied in parallel with
NOD1. We have previously shown that the NOD2 agonists,
MDP, have little effect on NOS2 activity in VSM cells. In the
current study, we have conﬁrmed these observations in
experiments where VSM cells and macrophages were treated
in parallel. Speciﬁcally, we found that MDP did not induce
NOS2 activity in either cell type. These observations
strengthen our assertion that NOD1 is the predominant
pathway for NOS2 induction in these cells. This result sup-
ports published data showing that NOD2 agonists are poor
inducers of cytokine production (Park et al., 2007) and vascu-
lar dysfunction (Cartwright et al., 2007b). In other studies,
activators of NOD receptors and activators of TLRs were found
to have a synergistic effect (Chamaillard et al., 2003; Fritz
et al., 2005; van Heel et al., 2005; Tada et al., 2005; Masumoto
et al., 2006). However, in our study, where NOS2 was the gene
of interest, we found no interaction between LPS and FK565
in macrophages, and only a very modest interaction in VSM
cells. Nevertheless, because macrophages represent a pheno-
typically highly diverse cell population, the role of NOD1
signalling pathways in macrophages from different sources
may well vary and requires further study before extensive
conclusions can be drawn.
The pathway by which TLR4 signals in the VSM component
of blood vessels is well worked out (Yang et al., 2005; Cart-
wright et al., 2007a; Son et al., 2008). However, this is the ﬁrst
study to investigate NOD1-mediated NOS2 induction in a
vascular model. Firstly, we demonstrated that similar to NOS2
induced via the TLR4 pathway, the glucocorticoids dexam-
ethasone and prednisolone inhibited NOS2 induced by FK565
in VSM cells. NF-kB is a major inﬂammatory factor triggered
by both TLRs and NLRs (Shaw et al., 2008). Accordingly, the
effects induced by TLR4 and NOD1 agonists were blocked by
the IKK-2 inhibitor SC-514 in both types of cell. More
recently, it was shown that Gram-negative bacterial LPS is also
able to activate MAPK signalling pathways in macrophages
(Shaw et al., 2008). Our data conﬁrm that the p38 MAPK and
ERK1/2 pathways are needed for NOS2 induction in VSM cells
and J774.2 macrophages. The role of JNK is, however, uncer-
tain in this cell system and requires further study. In addition,
the apparent lack of speciﬁcity of SP 600125 in murine mac-
rophages highlights that caution must be applied when
drawing conclusions using these compounds.
In other cell types, the details of how activation of NF-kB
and MAPK is linked to TLR4 and NOD1 are not clearly estab-
lished, but different reports have suggested that PKC and
some tyrosine kinases could be involved in these signalling
pathways. Several broad inhibitors of PKC isoforms have been
demonstrated to be effective in inhibiting secretion of pro-
inﬂammatory cytokines following TLR4 activation in mac-
rophages, neutrophils and neurones (Asehnoune et al., 2005;
Song et al., 2007). Gö6983 and Gö6976 were used in this
study to assess the role of PKC in the induction of NOS2 by
TLR4 and NOD1 agonists. Gö6983, which at the concentra-
tion tested shows selectivity for the conventional (a, bI, bII, g),
some novel (d) and atypical (i/l, z) PKC isoforms (Way et al.,
2000), had no effect on NOS2 activity induced in VSM cells by
FK565 or that in macrophages induced by LPS. By contrast,
Gö6976, which in addition to the conventional isoforms, also
inhibits PKCm (Way et al., 2000) inhibited NOS2 activity
Figure 4 Role of protein kinase C isoforms (PKC) in TLR4 and NOD1 signalling pathways. VSM cells (A) and J774.2 macrophages (B) were
treated with the PKC inhibitors Gö6983 (0.1 mM) and Gö6976 (0.1 mM). NOS2 activity was induced by FK565 (10 nM) in VSM cells and by
LPS (1 mg·mL
-1) in macrophages. Data are the mean  SEM of n = 6 for J774.2 cells and n = 15 for VSM cells and are expressed as a percentage
of the response to the FK565 or LPS alone (CTRL). Western blotting images for NOS2 protein (C,D) showing the effects of Gö6976 and
Gö69683 (both at 0.1 mM) on NOS2 expression in VSM cells (C) and macrophages (D) (n = 3). Data were analysed using one-sample t-test
for normalized data, *P < 0.05 and ***P < 0.001.
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activity induced in VSM cells by FK565. As the only isoform
known to be sensitive to Gö6976 and insensitive to Gö6983 is
PKCm (also known as protein kinase D or PKD), our data
suggest that this isoform might be involved in the responses
induced by LPS in macrophages. PKD isoforms are present in
a wide variety of cells where they control cellular processes
such as cell proliferation, apoptosis or immune responses
(Van Lint et al., 2002; Song et al., 2007). PKDs have been
shown to control gene transcription by activating NF-kB and
MAPK pathways, and by inhibiting HDACs (Matthews et al.,
2006). PKD can be activated by a variety of stimuli via PKC-
dependent and -independent pathways (Johannessen et al.,
2007). Previous reports have shown that the involvement of
speciﬁc PKC isoforms seems to be time dependent. Because we
analysed the effects of these inhibitors after 24 h, the possi-
bility that other PKC isoforms are involved in earlier events
cannot be ruled.
As pointed out in the introduction, the signalling events
associated with NOD1 are not completely understood. It is
clear that RIP2 and NOD1 interact, in order for downstream
signalling to occur (Kobayashi et al., 2002), but whether this
interaction provides a mere physical link between NLR and
downstream effectors molecules or whether the kinase activity
ofRIP2playsadirectroleintransductionmechanismsremains
tobedetermined(Windheimet al.,2007).Inthepresentstudy,
PP2, a potent inhibitor of RIP2 (Windheim et al., 2007), inhib-
ited the production of NO induced by FK565 in VSM cells.
Because activation of NF-kB by TLR agonists has also been
shown to signal through this kinase, RIP2 was proposed as a
point of synergy (Kobayashi et al., 2002). However, in our
model, inhibition of RIP2 had little or no effect on macroph-
ages stimulated with either LPS or E. coli. These results suggest
that RIP2 kinase activity is required for NOS2 induction fol-
lowing NOD1 activation. SB 203580, which is commonly used
as a speciﬁc inhibitor of p38 MAPK, has also been found to
inhibit RIP2 kinase activity in vitro with even greater potency
(Argast et al., 2005; Windheim et al., 2007). Therefore, the
inhibition observed in the production of NO by VSM cells
following treatment with SB 203580 might be revealing the
consequences of inhibiting both p38 MAPK and RIP2.
Activation of TLRs can result in the activation of caspase 1
and caspase 8 (Maelfait et al., 2008; Shaw et al., 2008) by the
inﬂammasome complex, which induces the maturation of the
pro-inﬂammatory cytokines IL-1b and IL-18. Functional
co-operation has also been observed between inﬂammasome
NLRs and NOD1 receptors, generating controversy over
whether inﬂammasome NLRs are able to sense products of the
degradation of PGN (Shaw et al., 2008). When we analysed
the role of the inﬂammasome in NOD1 responses using
FK565 or whole Gram-negative bacteria in VSM cells, we
found that neither the pan-caspase inhibitor Z-VAD-fmk nor
the binding antibodies for IL-1b or IL-18 affected the produc-
tion of NO. By contrast, Z-VAD-fmk inhibited TLR4-mediated
NOS2 activity and protein expression, and reduced cell viabil-
ity in macrophages stimulated with LPS or E. coli. The effects
of Z-VAD-fmk on NOS2 induction, but not on macrophage
viability, were mimicked when caspase 1 and caspase 8 were
inhibited selectively using Z-WEHD-fmk and Z-IETD-fmk
respectively. It should be noted that, in contrast to some
preceding reports, in the current study where NOS2 activity
was our readout, no account was taken of any inﬂuence of
exogenous or endogenous ATP. Finally, our data suggest that
activation of caspases and PKD are both necessary and speciﬁc
events for the induction of NOS2 following TLR4 activation
in macrophages. It is noteworthy that caspase-dependent acti-
vation of PKD has been demonstrated both in vitro and in vivo
(Endo et al., 2000; Van Lint et al., 2002).
In addition to immune cells, structural cells of the cardio-
vascular system including VSM cells sense pathogens and
danger signals directly, clearly contributing to the develop-
ment of septic shock and atherosclerosis. In sepsis or vascular
inﬂammation, the endothelium tends to become activated,
resulting in recruitment of immune cells to the site of injury.
However, if the inﬂammation persists, the endothelium can
become dysfunctional with reduced endothelium-dependent
dilator responses (Clapp et al., 2004). Under these conditions,
the underlying VSM becomes activated by PAMPs or cytok-
ines, and expresses inducible enzymes including NOS2
(Cartwright et al., 2007b; Mitchell et al., 2007), leading to
hypo-responsiveness to constrictor agents. This impaired vas-
cular contractility is independent of the endothelium (Julou-
Figure 5 Effects of Src and serine/threonine kinase inhibitor PP2 on
the induction of NOS2 by TLR4 and NOD1 agonists. Effects of the Src
and serine/threonine kinase inhibitor PP2 (1 nM–1 mM) on the ability
of FK565 or LPS to induce nitrite production in VSM cells (A) and
macrophages(B).ThedataarethemeanSEMofn=9forJ774.2cells
and n = 15 for VSM cells, and are expressed as a percentage of the
response to the FK565 or LPS alone (CTRL). (C) Representative image
showing that 0.1 mM PP2 inhibited NOS2 induction in VSM cells by
NOD1 activation (n = 3). Data were analysed using one-sample t-test
for normalized data, *P < 0.05, **P < 0.01 and ***P < 0.001.
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British Journal of Pharmacology (2010) 160 1997–2007Schaeffer et al., 1990; Szabo et al., 1993) and associated
speciﬁcally with the induction of NOSII in the VSM compo-
nent of blood vessels (Bishop-Bailey et al., 1997)
In vivo, the host is exposed to multiple ligands derived from
Gram-negative bacteria, including both NOD1 and TLR4 ago-
nists. Here, we have identiﬁed some similarities and differ-
ences in how VSM cells and macrophages sense Gram-
negative PAMPs. Our ﬁndings show a novel and selective role
for NOD1 receptors in VSM cells. Our data also show that the
signalling pathways resulting in NOS2 induction are separate
for NOD1 and TLR4, but converge at the level of NF-kB and
MAPK. An effective host response to infection and injury
relies on the ability to regulate the spatial and temporal pat-
terns of the signalling pathways activated during the inﬂam-
matory response. The data presented here suggest that NOD1
is a central PRR pathway in VSM cells, and highlight NOD1 as
a potential novel therapeutic target for the treatment of vas-
cular inﬂammation.
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